Active Recombinant Human EphA2 protein, His-tagged

• Cat.No.: EPHA2-2027H
• Product Overview: Recombinant Human EphA2 protein(Met1-Asn534)(P29317), fused with His tag, was expressed in HEK293.

Specification

• Source: HEK293
• Species: Human
• Tag: His
• Form: Lyophilized from sterile 20mM Tris, 150mM NaCl, pH 7.5.Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA.
• Bio-activity: Measured by its binding ability in a functional ELISA. Immobilized Human EphA2 His at 2 μg/ml (100 μl/well) can bind Human Ephrin-A1 His & hFc, the EC50 of Human Ephrin-A1 His & hFc is 4.0-20.0 ng/mL.
• Molecular Mass: The recombinant human EPHA2 consists of 522 amino acids and predicts a molecular mass of 57.6 KDa. It migrates as an approximately 65-75 KDa band in SDS-PAGE under reducing conditions.
• Protein length: Met1-Asn534
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Purity: > 95 % as determined by SDS-PAGE
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C
  Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: EPHA2 EPH receptor A2 [ Homo sapiens ]
• Official Symbol: EphA2
• Synonyms: EPHA2; EPH receptor A2; ECK, EphA2; ephrin type-A receptor 2; soluble EPHA2 variant 1; tyrosine-protein kinase receptor ECK; epithelial cell receptor protein tyrosine kinase; ECK; CTPA; ARCC2; CTPP1
• Gene ID: 1969
• mRNA Refseq: NM_004431
• Protein Refseq: NP_004422
• MIM: 176946
• UniProt ID: P29317

Reviews

12/21/2022

The protein has low cytotoxicity.

02/03/2022

EPHA2 has good stability, and the test results of heat resistance, acid and alkali resistance and protease degradation resistance are good.

03/31/2021

Kinetic parameters such as enzymatic reaction rate and binding affinity were tested, and the protein performed well.

Q&As

What are the treatment strategies for EPHA2?

Therapeutic strategies for EPHA2 include inhibition of its expression, blocking its signal transduction pathway, and modulating its interaction with ligands. These strategies may involve the use of small molecule inhibitors, antibodies, or other types of therapeutics.

How does EPHA2 expression level relate to the occurrence and progression of the disease?

The expression level of EPHA2 is associated with the occurrence and progression of a variety of diseases. For example, in tumors such as lung, breast, and colorectal cancer, EPHA2 expression levels may be elevated and correlated with the degree of malignancy and poor prognosis of the tumor.

How does EPHA2 expression level relate to tumor prognosis?

In some tumors, EPHA2 expression levels are associated with poor prognosis in patients. For example, patients with lung cancer who express EPHA2 often have shorter survival. Therefore, the expression level of EPHA2 may be one of the indicators to predict tumor prognosis.

How can diseases be diagnosed by detecting EPHA2 expression levels?

Some diseases can be diagnosed by measuring EPHA2 expression levels, such as immunohistochemistry, western blotting, and real-time PCR.

Could EPHA2 be used as a target for the treatment of certain diseases?

Yes, EPHA2 can be used as a target for the treatment of certain diseases. For example, inhibition of EPHA2 expression can inhibit tumor growth and spread, so EPHA2 can serve as a potential therapeutic target. In addition, regulating the expression level of EPHA2 may also be helpful in the treatment of diseases such as the nervous system and cardiovascular system.

What is the role of EPHA2 in cancer metastasis?

EPHA2 can promote cancer metastasis and affect the spread and spread of cancer by regulating processes such as invasion and migration of tumor cells. Therefore, inhibition of EPHA2 expression or blocking its signal transduction pathway may have a potential therapeutic effect on inhibiting cancer metastasis.